4-(4-phenylpiperazin-1-yl)dihydrofuran-2(3H)-one | 1403336-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-phenylpiperazin-1-yl)dihydrofuran-2(3H)-one
• 英文别名: ϒ-butyrolactone；4-(4-Phenylpiperazin-1-yl)oxolan-2-one；4-(4-phenylpiperazin-1-yl)oxolan-2-one
• CAS: 1403336-65-1
• 化学式: C₁₄H₁₈N₂O₂
• 分子量: 246.309
• InChiKey: AQYBTGFKLMVQLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-苯基哌嗪 、 2(5H)-呋喃酮 以 二氯甲烷 为溶剂， 反应 3.5h， 以45%的产率得到4-(4-phenylpiperazin-1-yl)dihydrofuran-2(3H)-one
  参考文献：
  名称：

  Search for anticonvulsant and analgesic active derivatives of dihydrofuran-2(3H)-one

  摘要：

  A series of derivatives of dihydrofuran-2(3H)-one (gamma-butyrolactone, GBL) was synthesized and tested for anticonvulsant, neurotoxic and analgesic activity. In the anticonvulsant screening 10 lactones were effective in the maximal electroshock test (MES) at the highest doses (300 and 100 mg/kg, 0.5 h, ip, mice). Statistical analysis showed correlation between the anticonvulsant activity and relative lipophilicity parameters determined by experimental and computational methods (R-M0, ClogP and M log P). Preliminary antinociceptive evaluation of selected derivatives revealed strong analgesic activity. The majority of the tested compounds showed high efficacy in animal models of acute pain (hot plate and writhing tests) and strong local anesthetic activity (modified tail immersion test). The obtained ED50 values were comparable with such analgesics as acetylsalicylic acid and morphine. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.08.037

文献信息

• Methods for Treating Central Nervous System Disorders Using VDAC Inhibitors
  申请人：The National Institute for Biotechnology in the Negev Ltd.

  公开号：US20180078548A1

  公开（公告）日：2018-03-22

  The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

  本发明涉及使用与电压依赖性孔道（VDAC）相互作用的小有机化合物用于治疗与中枢神经系统（CNS）疾病相关的疾病，包括精神病性障碍、情绪障碍和神经退行性疾病。具体来说，本发明涉及使用取代哌嗪和哌啶衍生物以及包含同样物质的药物组合物用于治疗包括精神分裂症、情绪障碍和神经退行性疾病在内的精神病性障碍。
• Methods for treating central nervous system disorders using VDAC inhibitors
  申请人：The National Institute for Biotechnology in the Negev Ltd.

  公开号：US10434099B2

  公开（公告）日：2019-10-08

  The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

  本发明涉及与电压依赖性阴离子通道（VDAC）相互作用的小型有机化合物用于治疗与中枢神经系统（CNS）紊乱有关的疾病，包括精神障碍、情绪障碍、神经退行性疾病。本发明尤其涉及取代的哌嗪和哌啶衍生物以及包含这些衍生物的药物组合物用于治疗包括精神分裂症在内的精神障碍、情绪障碍和神经退行性疾病。
• Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction
  申请人：THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.

  公开号：US10508091B2

  公开（公告）日：2019-12-17

  Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.

  本文提供了哌嗪和哌啶衍生物、它们的合成及其在抑制 VDAC 低聚、细胞凋亡和线粒体功能障碍方面的用途。还提供了与上述过程相关的疾病（如阿尔茨海默病）的治疗方法。
• Methods for treating central nervous system disorders using vdac inhibitors
  申请人：The National Institute for Biotechnology in the Negev Ltd.

  公开号：US10946013B2

  公开（公告）日：2021-03-16

  The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.

  本发明涉及与电压依赖性阴离子通道（VDAC）相互作用的小型有机化合物用于治疗与中枢神经系统（CNS）紊乱有关的疾病，包括精神障碍、情绪障碍、神经退行性疾病。本发明尤其涉及取代的哌嗪和哌啶衍生物以及包含这些衍生物的药物组合物用于治疗包括精神分裂症在内的精神障碍、情绪障碍和神经退行性疾病。
• NOVEL PIPERAZINE AND PIPERIDINE DERIVATIVES, THEIR SYNTHESIS AND USE THEREOF IN INHIBITING VDAC OLIGOMERIZATION, APOPTOSIS AND MITOCHONDRIA DYSFUNCTION
  申请人：THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.

  公开号：US20180118700A1

  公开（公告）日：2018-05-03

  Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said processes, e.g. Alzheimer's disease.